Chronic activation of tubulin tyrosination in HCM mice and in human iPSC-engineered heart tissues improves heart function
Preprint
Abstract
Rationale: Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disorder caused by sarcomeric gene variants and associated with left ventricular (LV) hypertrophy and diastolic dysfunction. The role of the microtubule network has recently gained interest with the findings that α-tubulin detyrosination (dTyr-tub) is markedly elevated in heart failure. Acute reduction of dTyr-tub by inhibition of the detyrosinase (VASH/SVBP complex) or activation of the tyrosinase (tubulin tyrosine ligase, TTL) markedly improved contractility and reduced stiffness in human failing cardiomyocytes, and thus poses a new perspective for HCM treatment. Objective: In this study, we tested the impact of chronic tubulin tyrosination in a HCM mouse model ( Mybpc3 -knock-in; KI), in human HCM cardiomyocytes and in SVBP-deficient human engineered heart tissues (EHTs). Methods and Results: AAV9-mediated TTL transfer was applied in neonatal wild-type (WT) rodents and 3-week-old KI mice and in HCM human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. We show that i) TTL for 6 weeks dose-dependently reduced dTyr-tub and improved contractility without affecting cytosolic calcium transients in WT cardiomyocytes; ii) TTL for 12 weeks improved diastolic filling, cardiac output and stroke volume and reduced stiffness in KI mice; iii) TTL for 10 days normalized cell hypertrophy in HCM hiPSC-cardiomyocytes; iv) TTL induced a marked transcription and translation of several tubulins and modulated mRNA or protein levels of components of mitochondria, Z-disc, ribosome, intercalated disc, lysosome and cytoskeleton in KI mice; v) SVBP-deficient EHTs exhibited reduced dTyr-tub levels, higher force and faster relaxation than TTL-deficient and WT EHTs. RNA-seq and mass spectrometry analysis revealed distinct enrichment of cardiomyocyte components and pathways in SVBP-KO vs. TTL-KO EHTs. Conclusion: This study provides the first proof-of-concept that chronic activation of tubulin tyrosination in HCM mice and in human EHTs improves heart function and holds promise for targeting the non-sarcomeric cytoskeleton in heart disease.Keywords
All Related Versions
- Published version: Circulation Research, 135 (9), 910.
This publication has 51 references indexed in Scilit:
- Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in miceEMBO Molecular Medicine, 2013
- Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic CardiomyopathyMolecular Therapy Nucleic Acids, 2013
- Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in miceJournal of Molecular and Cellular Cardiology, 2012
- Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophyBasic Research in Cardiology, 2011
- Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard MaterialHuman Gene Therapy, 2010
- Nonsense-Mediated mRNA Decay and Ubiquitin–Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic MiceCirculation Research, 2009
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Measurement of cardiac function using pressure–volume conductance catheter technique in mice and ratsNature Protocols, 2008
- MURC, a Muscle-Restricted Coiled-Coil Protein That Modulates the Rho/ROCK Pathway, Induces Cardiac Dysfunction and Conduction DisturbanceMolecular and Cellular Biology, 2008
- Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus endsJournal of Cell Biology, 2006